Gilead Sciences gained rights over GLPG1690, Galapagos‘ investigational therapy for idiopathic pulmonary fibrosis (IPF), as part of a…
Articles by Patricia Inácio, PhD
Genetic variants of the MUC5AC gene may contribute to the development of idiopathic pulmonary fibrosis (IPF), a study…
Treatment with Esbriet (pirfenidone) slows the worsening of breathlessness in patients with more severe idiopathic pulmonary fibrosis (IPF),…
Increased levels of specific proteins found in blood, namely C-reactive protein, lactate dehydrogenase, and total cholesterol, may predict the risk…
Bridge Biotherapeutics’ investigational therapeutic candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) was found to be safe and well-tolerated in the…
Rosavin, an active compound found in the plant Rhodiola rosea, commonly known as golden root or Aaron’s rod, can…
Exposure to cigarette smoking and lipopolysaccharides, components of the cell wall of certain bacteria, can lead to more severe lung…
Proliferation and inflammation of human lung fibroblasts is controlled by small RNA molecules called long non-coding RNAs, a study reports.
Rare variants in genes that regulate the end regions of chromosomes — called telomeres — are linked with worse survival…
High levels of the protein vimentin in the lung tissue of patients with idiopathic pulmonary fibrosis (IPF) contribute…